

The logo for Seeking Alpha, with the text 'Seeking Alpha' in white and a yellow Greek letter alpha symbol to the right, all on a dark red background.

## Human Genome Sciences Inc. Q1 2009 Earnings Call Transcript

### Question-and-Answer Session

---

**Operator**

(Operator Instructions). And we will take our first question from Joe Schwartz with Leerink Swann.

**Joe Schwartz - Leerink Swann**

Hi, thanks for taking my question. It sounds like you are working diligently to secure additional orders for ABthrax. How comfortable are you that more orders might be seen and what sort of a timeframe should we expect?

**Thomas Watkins**

Joe, I'm going to ask Jim Davis to handle that question.

**Jim Davis**

Thanks, Joe, for the question. We are working diligently on this, and we are optimistic that we will get additional orders. Unfortunately, at this time, I can't give you any more concrete details of when or how much, but we'll let you know as soon as we do have a definitive contract.

**Joe Schwartz - Leerink Swann**

Great, thanks. And then as far as the remainder of the sales to the Strategic National Stockpile in the U.S. goes, any more guidance on when the remainder might be booked?

**Jim Davis**

We said that we would complete the deliveries this quarter, the second quarter.

**Joe Schwartz - Leerink Swann**

Okay, great. Thanks.

**Operator**

And we'll go next to Geoff Porges with Bernstein.

**Geoff Porges - Bernstein**

Thanks very much for taking the question. Just a couple. First, you mentioned, Tom, the pre-BLA. Could you give us a sense of what's the process of scheduling, when might they happen and would

you communicate the outcome of those meetings? And secondly, any plans then to repurchase any more of the debt? Do you think that's feasible given your current cash position?

**Tom Watkins**

Geoff, let me answer the second question first, and then I am going to ask David Stump to answer the first question. I would say on the debt, we have no specific plans to do any additional repurchase at this time. We are confident partially because of our good cash position that we have sufficient flexibility to deal with the debt and not have that debt inhibit our ability to move the company forward, and as Tim stated, allow us to complete the work that's ongoing, get the global marketing applications filed and properly launch the product.

David, why don't you speak to the question on pre-BLA meetings, please?

**David Stump**

Our goal has been to have these meetings both with the FDA here in the U.S. and in Europe in the second quarter. We've requested those meeting dates, don't have them all finally locked in, but I am optimistic we can get those done this quarter for the process, while we've asked for the dates and putting together our briefing books for those meetings. And we will have them ready for any dates we get.

Copyright © 2009 CBS Interactive, Inc. All Rights Reserved.